Loading
A phase 1/2 trial of lutetium-177 rhPSMA-10.1 in prostate cancer, run by Blue Earth Therapeutics Ltd, now recruiting.
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection is a phase 1/2 interventional study registered as NCT05413850 by Blue Earth Therapeutics Ltd, with 82 participants planned, started 2022-07-20 and due to reach its primary completion in 2026-08-27. Interventions recorded: Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only). Conditions listed: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FAPI PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares Radioligand therapy (beta emitters), Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Radioligand therapy (beta emitters), Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Radioligand therapy (beta emitters), Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Radioligand therapy (beta emitters), Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/